NCT03414450View on ClinicalTrials.gov

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 25, 2018

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2023

Conditions
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)Ph- Acute Lymphoblastic Leukemia (Ph-ALL)Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)
Interventions
DRUG

ETC-1907206

ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.

DRUG

dasatinib

dasatinib tablets at 140 mg will be dosed every day

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

20874

The Center for Cancer and Blood Disorders, Bethesda

30322

Winship Cancer Institute, Emory University, Atlanta

77030

MD Anderson Cancer Center, Houston

97239

Oregon Health & Science University, Portland

169608

Singapore General Hospital, Singapore

Sponsors
All Listed Sponsors
collaborator

Chiltern International Inc.

INDUSTRY

lead

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

OTHER_GOV